cITIUS

Citius (CTXR) Announces Results of Mino-Lok Study.

"Mino-Lok has the potential to change the standard of care, which currently calls for a procedure to remove and replace the infected...
Dalrada, Biotech Stock Review

Dalrada (DFCO) Announces Form S-1 Registration Declared Effective by SEC

SAN DIEGO , Nov. 3, 2020 /PRNewswire/ -- Dalrada Financial Corp. (OTC Pink: DFCO), is pleased to announce that its Form S-1 registration statement has been declared...
Hapbee, Biotech Stock Review

Telehealth App Hapbee (HAPB) Goes Public and More.

1. Hapbee (HAPB) $0.30, Going Public.2. Saying Goodbye to Immunomedics (IMMU) $86.3. Adding Biosig (BSGM) $2.95, to Watch...
Dalarada Health, Biotech Stock Review

Dalrada Cervical Cancer Testing Kit Study.

KEY TAKEAWAYS Dalrada Corp (DFCO) LIVE QUOTE
biotech stock review

Dalrada’s ‘VIA’ Test Screening Kit Goes Head to Head with ‘Pap’ Smear Test Screening.

DALRADA aims to introduce its VIA Test kit to females in India - of which there is 497 million.
Issam Radd

Citius Pharma (CTXR) Shareholder Letter | Year Ahead Roadmap.

2021 and 2020 Milestones In Plain Sight. Locked and Loaded for most of 2020 - many major milestone...

Citius Pharma (CTXR) Video Presentation.

Chairman Leonard Mazur Discusses: Mino-Lok Treatment for Infected Catheters. Novellus Stem Cell Treatment...
American BriVision

American BriVision’s (ABVC) Clinical Study Sparks Interest From Potential Partners.

Is Wall Street Missing American Brivision's Full Clinical Safety and Efficacy Study? We Think it has. Potential...

There’s Simply No Loyalty Anymore.

TODAY'S LETTER Frontier Bio (FBIO) $3.90. We Have Another Double! American BriVision (ABVC) $4.00. Wait, What? Yet...
Roland Rick Perry, Biotech Stock Review, Frontier Bio

And We Have Another Double. Frontier Bio (FBIO) Crosses $4.00.

Sometimes we Can't Beleive Our Luck Over the Last Couple Years. But There You Have it, at Least we Know It's...

Latest article

Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!

Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.

CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...

GeoVax (GOVX) Launches Vaccine Manufacturing System.

GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System Manufacturing Process for Phase 3 and Commercial Production...